Provided below is a list of the clinical trials that are currently in progress to evaluate new mesothelioma treatment protocols. Please note that the enrollment period for the following mesothelioma studies has concluded and no new participants are being recruited at this time.
The purpose of these studies is to determine both the safety and effectiveness of new mesothelioma drugs and treatment therapies. Click on a link to learn more about a study and to get recent update information.
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: April 27, 2020
Status: Active, not recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Conditions: Mesothelioma
Last Updated: April 24, 2020
Status: Active, not recruiting
CAR T Cells in Mesothelin Expressing Cancers
Conditions: Adenocarcinoma, Mesothelioma, Fallopian Tube Neoplasms, Adenocarcinoma of Lung
Last Updated: April 23, 2020
Status: Active, not recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: April 23, 2020
Status: Active, not recruiting
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
Conditions: Mesothelioma
Last Updated: April 20, 2020
Status: Active, not recruiting
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Conditions: Neoplasms
Last Updated: April 17, 2020
Status: Active, not recruiting
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: April 17, 2020
Status: Active, not recruiting
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Mesothelioma, Lung Neoplasms, Neoplasms
Last Updated: April 14, 2020
Status: Active, not recruiting
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Conditions: Neoplasms
Last Updated: March 18, 2020
Status: Active, not recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma
Last Updated: March 16, 2020
Status: Active, not recruiting
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Conditions: Mesothelioma, Pleural Effusion, Malignant, Pleural Effusion
Last Updated: March 12, 2020
Status: Active, not recruiting
Clinical and Histopathologic Characteristics of BAP1 Mutations
Conditions: Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma, Uveal Neoplasms
Last Updated: March 2, 2020
Status: Active, not recruiting
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Conditions: Neoplasms
Last Updated: February 26, 2020
Status: Active, not recruiting
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: February 25, 2020
Status: Active, not recruiting
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Conditions: Mesothelioma
Last Updated: February 11, 2020
Status: Active, not recruiting
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: February 6, 2020
Status: Active, not recruiting
A Study of LY3023414 in Participants With Advanced Cancer
Conditions: Mesothelioma, Neoplasms
Last Updated: February 3, 2020
Status: Active, not recruiting
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Conditions: Vaccinia, Mesothelioma, Pleural Effusion, Malignant, Pleural Effusion
Last Updated: January 17, 2020
Status: Active, not recruiting
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: January 14, 2020
Status: Active, not recruiting
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: January 2, 2020
Status: Active, not recruiting
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma
Last Updated: December 18, 2019
Status: Active, not recruiting
Diadem to Investigate the Activity and Safety of Durvalumab
Conditions: Mesothelioma
Last Updated: October 3, 2019
Status: Active, not recruiting
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Conditions: Mesothelioma
Last Updated: August 2, 2019
Status: Active, not recruiting
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: July 19, 2019
Status: Active, not recruiting
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: June 19, 2019
Status: Active, not recruiting
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: May 24, 2019
Status: Active, not recruiting
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Conditions: Mesothelioma
Last Updated: May 9, 2019
Status: Active, not recruiting
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: May 7, 2019
Status: Active, not recruiting
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Conditions: Lymphoma
Last Updated: May 3, 2019
Status: Active, not recruiting
Vinorelbine in Mesothelioma
Conditions: Mesothelioma
Last Updated: April 29, 2019
Status: Active, not recruiting
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: March 29, 2019
Status: Active, not recruiting
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Conditions: Mesothelioma
Last Updated: March 4, 2019
Status: Active, not recruiting
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
Conditions: Mesothelioma
Last Updated: February 27, 2019
Status: Active, not recruiting
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Conditions: Mesothelioma
Last Updated: February 11, 2019
Status: Active, not recruiting
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: October 31, 2018
Status: Active, not recruiting
Dasatinib in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 26, 2018
Status: Active, not recruiting
